Terms: = Bone cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2
382 results:
1. IFNα-induced BST2
Zheng C; Wang J; Zhou Y; Duan Y; Zheng R; Xie Y; Wei X; Wu J; Shen H; Ye M; Kong B; Liu Y; Xu P; Zhang Q; Liang T
Cell Rep; 2024 Apr; 43(4):114088. PubMed ID: 38602878
[TBL] [Abstract] [Full Text] [Related]
2. [Colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological analysis of eight cases].
Wang Q; Zhang Y; Tan C; Ni SJ; Huang D; Chang B; Sheng WQ; Wang L
Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):370-376. PubMed ID: 38556821
[No Abstract] [Full Text] [Related]
3. Fusion of old and new: Employing touch imprint slides for next generation sequencing in solid tumors.
Aydin Mericoz C; Eren OC; Kulac I; Firat P
Diagn Cytopathol; 2024 May; 52(5):264-270. PubMed ID: 38339821
[TBL] [Abstract] [Full Text] [Related]
4. Mosaic RASopathies concept: different skin lesions, same systemic manifestations?
Morren MA; Fodstad H; Brems H; Bedoni N; Guenova E; Jacot-Guillarmod M; Busiah K; Giuliano F; Gilliet M; Atallah I
J Med Genet; 2024 Apr; 61(5):411-419. PubMed ID: 38290824
[TBL] [Abstract] [Full Text] [Related]
5. Blockade of CD93 in pleural mesothelial cells fuels anti-lung tumor immune responses.
Zhang C; Nan X; Zhang B; Wu H; Zeng X; Song Z; Li S; Wang J; Xie S; Zhang G; Xiu H; Wang J; Guo J; Wang P; Cai Z; Zhen Y; Shen Y
Theranostics; 2024; 14(3):1010-1028. PubMed ID: 38250037
[No Abstract] [Full Text] [Related]
6. Demographics and additional haematologic cancers of patients with histiocytic/dendritic cell neoplasms.
Kemps PG; Kester L; Scheijde-Vermeulen MA; van Noesel CJM; Verdijk RM; Diepstra A; van Marion AMW; Dors N; van den Bos C; Bruggink AH; Hogendoorn PCW; van Halteren AGS
Histopathology; 2024 Apr; 84(5):837-846. PubMed ID: 38213281
[TBL] [Abstract] [Full Text] [Related]
7. Metastatic Undifferentiated Melanoma Mimicking a Primary bone Tumor: A Potential Diagnostic Pitfall.
Wills A; Dibbern M; Frierson HF; Raghavan SS
Am J Dermatopathol; 2024 Mar; 46(3):170-172. PubMed ID: 38170737
[TBL] [Abstract] [Full Text] [Related]
8. Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies.
Shen X; Dong P; Kong J; Sun N; Wang F; Sang L; Xu Y; Zhang M; Chen X; Guo R; Wang S; Lin Q; Jiang Z; Xu S; Zhang C; Bian Z; Wang W; Guo R
Cell Biochem Funct; 2023 Dec; 41(8):1343-1356. PubMed ID: 37823726
[TBL] [Abstract] [Full Text] [Related]
9. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
Badar T; Vanegas YAM; Nanaa A; Foran JM; Al-Kali A; Mangaonkar A; Murthy H; Alkhateeb HB; Viswanatha D; He R; Shah M; Yi CA; Litzow MR; Gangat N; Tefferi A; Patnaik MM
Blood Cancer J; 2023 Sep; 13(1):149. PubMed ID: 37735430
[TBL] [Abstract] [Full Text] [Related]
10. Comparative bioinformatic analysis of kras, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on kras G12C.
Boeschen M; Kuhn CK; Wirtz H; Seyfarth HJ; Frille A; Lordick F; Hacker UT; Obeck U; Stiller M; Bläker H; von Laffert M
Lung Cancer; 2023 Oct; 184():107361. PubMed ID: 37699269
[TBL] [Abstract] [Full Text] [Related]
11. Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung cancer Patients.
Leest PV; Janning M; Rifaela N; Azpurua MLA; Kropidlowski J; Loges S; Lozano N; Sartori A; Irwin D; Lamy PJ; Hiltermann TJN; Groen HJM; Pantel K; Kempen LCV; Wikman H; Schuuring E
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686200
[TBL] [Abstract] [Full Text] [Related]
12. Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.
Quintanilla-Martinez L; Laurent C; Soma L; Ng SB; Climent F; Ondrejka SL; Zamo A; Wotherspoon A; de Leval L; Dirnhofer S; Leoncini L
Virchows Arch; 2023 Sep; 483(3):281-298. PubMed ID: 37555980
[TBL] [Abstract] [Full Text] [Related]
13. RAS‑stimulated release of exosomal
Kim O; Tran PT; Gal M; Lee SJ; Na SH; Hwangbo C; Lee JH
Int J Mol Med; 2023 Sep; 52(3):. PubMed ID: 37503759
[TBL] [Abstract] [Full Text] [Related]
14. Clinicopathological Features and Prognosis of Lung Adenocarcinoma Patients With K-RAS Gene Mutation.
Sun D; Liu Y; Li P; Yang P; Yu G
Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):406-413. PubMed ID: 37338109
[TBL] [Abstract] [Full Text] [Related]
15. Testicular Rosai-Dorfman disease clonally related to CMML - Case report and literature review.
Fiegl A; Dirnhofer S; Juskevicius D; Zagrapan B; Dertinger S; Bösl A; Milos S; Brunner J; Bertolini F; Offner FA
Pathol Res Pract; 2023 Jul; 247():154548. PubMed ID: 37216748
[TBL] [Abstract] [Full Text] [Related]
16. Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis.
Li N; Lin P; Zuo Z; You MJ; Shuai W; Orlowski R; Manasanch EE; Li S; Xu J; Garces S; Jelloul FZ; Tang Z; Wang W; Medeiros LJ; Yin CC
Cancer Med; 2023 Jul; 12(13):14293-14304. PubMed ID: 37212518
[TBL] [Abstract] [Full Text] [Related]
17. Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study.
Ma K; Guo Q; Li X
BMC Pulm Med; 2023 May; 23(1):175. PubMed ID: 37208639
[TBL] [Abstract] [Full Text] [Related]
18. Schimmelpenning-Feuerstein-Mims syndrome induced by HRAS Gly12Ser somatic mosaic mutation: Case report and literature review.
Ono H; Yamaguchi R; Arai M; Togi S; Ura H; Niida Y; Shimizu A
J Dermatol; 2023 Sep; 50(9):1213-1215. PubMed ID: 37170693
[TBL] [Abstract] [Full Text] [Related]
19. Molecular markers of metastatic disease in kras-mutant lung adenocarcinoma.
Boiarsky D; Lydon CA; Chambers ES; Sholl LM; Nishino M; Skoulidis F; Heymach JV; Luo J; Awad MA; Janne PA; Van Allen EM; Barbie DA; Vokes NI
Ann Oncol; 2023 Jul; 34(7):589-604. PubMed ID: 37121400
[TBL] [Abstract] [Full Text] [Related]
20. Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type.
Dalens L; Lecuelle J; Favier L; Fraisse C; Lagrange A; Kaderbhai C; Boidot R; Chevrier S; Mananet H; Derangère V; Truntzer C; Ghiringhelli F
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108755
[TBL] [Abstract] [Full Text] [Related]
[Next]
